Novo Nordisk, OpenAI

Digest more
Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development
By Maggie Fick LONDON, April 14 (Reuters) - Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly in the immensely lucrative weight-loss drug market, said on Tuesday it is partnering with OpenAI to deploy artificial intelligence across its business,

Continue reading

Wegovy Maker Novo Nordisk Strikes Deal With OpenAI to Speed Up Drug Discovery
The Wegovy pill saw the fastest take-up in weight-loss drug history. Novo Nordisk only narrowly lifted guidance
Novo Nordisk's weight-loss pill exceeds forecasts, closing gap with Lilly
COPENHAGEN/LONDON, May 6 (Reuters) - Novo Nordisk (NOVOb.CO) beat first-quarter profit forecasts and nudged up ​its full-year outlook on Wednesday, helped by stronger-than-expected sales of its new we...

Continue reading

Novo Nordisk Stock Rallies Thanks to Wegovy Pill
Novo Nordisk shares rise on strong demand for GLP-1 pill
Shares in Novo Nordisk jump after Wegovy pill sales smash forecasts
It continued: "Coupled with total prescriptions for the first quarter of around 1.3m and more than 2m since launch, it marks the strongest ever GLP-1 volume launch in the US."

Continue reading

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill
The Wegovy pill saw the fastest take-up in weight-loss drug history. Novo Nordisk only narrowly lifted guidance.
AOL
Novo Nordisk partners with OpenAI to speed drug discovery
The race to develop the next generation of medicines just got faster. At least, that is the bet Novo Nordisk is making. The Danish pharmaceutical company announced a strategic partnership with OpenAI on April 14, covering everything from drug discovery to ...
NJBIZ
Novo Nordisk teams with OpenAI to speed drug development
Pharmaceutical giant Novo Nordisk is teaming with OpenAI to deploy artificial intelligence in an effort to speed up drug development. The Danish company said the collaborationwill pilot AI to analyze complex datasets, identify promising new drugs and ...
Morningstar
Wegovy Maker Novo Nordisk Strikes Deal With OpenAI to Speed Up Drug Discovery — Update
Novo Nordisk said it would work with ChatGPT maker OpenAI on how to leverage artificial intelligence to discover new drugs, the latest AI partnership in the medical field as healthcare companies seek to harness the technology to get ahead of the competition.
MobiHealthNews
OpenAI partners with Novo Nordisk for AI drug discovery
OpenAI has announced a strategic partnership with pharma giant Novo Nordisk to use advanced AI for drug discovery, including analyzing complex datasets, identifying drug candidates and reducing the time from research to when a patient receives a medication.
Hosted on MSN
Novo Nordisk partners with OpenAI as AI drug discovery hopes mount
Novo Nordisk is partnering with OpenAI to "bring new and better treatment options to patients faster," the Danish drugmaker said Tuesday. "Integrating AI in our everyday work gives us the ability to analyse datasets at a scale that was previously ...
Computer Weekly
Novo Nordisk partners with OpenAI to AI-power drug development
Danish pharmaceutical company Novo Nordisk has partnered with OpenAI to support drug research and development. Through the partnership, Novo Nordisk said it plans to deploy advanced artificial intelligence (AI) capabilities to analyse complex datasets ...